- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Gastro-oesophageal cancers
- Meeting Date: May 2022
- Public Summary Document (PSD) May 2022 PBAC Meeting - (PDF 962KB)
- Public Summary Document (PSD) May 2022 PBAC Meeting - (Word 366KB)
Pembrolizumab – May 2022
Pembrolizumab: Solution concentrate for I.V. infusion 100 mg in 4 mL; Keytruda® – May 2022
Last updated
26 August 2022